13F Holdings
中文EN

BBIO BridgeBio Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1743881 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY167.3%
TTM net income YoY29.0%
TTM EPS YoY28.0%
Revenue 3-yr CAGR364.6%
Net income 3-yr CAGR—

Margins

Gross margin94.3%
Operating margin-38.5%
Net margin-59.8%
FCF margin-39.1%
EBITDA margin-38.0%

Returns

ROE—
ROA-35.8%
ROIC (approx.)—
Asset turnover0.60x

Leverage & solvency

Liabilities / assets176.5%
Debt / equity—
Current ratio2.09x
Interest coverage-7.13x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$502.08M$221.90M$9.30M$77.65M$69.72M
Cost of revenue$20.96M$3.88M$2.45M$3.43M$3.11M
Gross profit$481.11M$218.02M$6.86M$74.21M$66.60M
R&D expense$451.95M$506.46M$455.71M$399.46M$451.02M
SG&A expense$531.23M$288.93M$150.59M$143.19M$192.21M
Operating income-$523.41M-$592.97M-$607.37M-$512.20M-$576.63M
Interest expense$53.10M$90.99M$81.29M$80.44M$46.78M
Pretax income-$732.50M-$542.19M-$653.25M-$484.65M-$586.48M
Income tax$435,000$1.15M$0$0—
Net income-$724.93M-$535.76M-$643.20M-$481.18M-$562.54M
EBITDA-$517.98M-$586.90M-$600.88M-$505.43M-$570.79M
EPS (basic)-3.78-2.88-3.95-3.26-3.90
EPS (diluted)-3.78-2.88-3.95-3.26-3.90
Weighted avg. shares (diluted)191.53M186.08M162.79M147.47M144.36M
Balance sheet
Cash & equivalents$570.12M$681.10M$375.94M$376.69M$393.77M
Short-term investments$17.36M$0$0$51.58M$393.74M
Receivables$139.44M$4.72M$1.75M——
Inventory$26.75M$0———
Current assets$797.75M$720.69M$477.59M$548.85M$888.86M
PP&E, net$5.37M$7.01M$11.82M$14.57M$30.07M
Intangibles$28.08M$23.93M$26.32M$28.71M$44.93M
Total assets$936.02M$919.34M$546.38M$623.04M$1.01B
Current liabilities$287.97M$154.40M$143.84M$121.43M$135.07M
Long-term debt$2.01B$437.34M$446.44M$430.99M$430.75M
Total debt$2.01B$437.34M$446.44M$430.99M$430.75M
Total liabilities$3.01B$2.38B$1.89B$1.87B$1.88B
Shareholders' equity-$2.09B-$1.47B-$1.35B-$1.25B-$870.41M
Net debt$1.44B-$243.76M$70.51M$54.30M$36.98M
Shares outstanding194.77M190.04M175.08M150.63M147.34M
Cash flow statement
Operating cash flow-$445.91M-$520.73M-$527.72M-$419.49M-$497.93M
Capital expenditure$1.10M$933,000$1.31M$4.82M$13.25M
Free cash flow-$447.01M-$521.66M-$529.03M-$424.31M-$511.18M
Investing cash flow-$24.49M$60.78M$54.03M$453.15M-$200.83M
Financing cash flow$359.29M$748.46M$451.54M-$13.13M$736.45M
Depreciation & amortization$5.43M$6.08M$6.49M$6.77M$5.84M
Stock-based compensation$133.02M$95.80M$108.71M$91.56M$99.50M
Share buybacks$48.28M$0$0$0$200.00M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.